---
title: Metformin and Core Temperature in Obese and Lean Males
nct_id: NCT02783053
overall_status: COMPLETED
phase: NA
sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
study_type: INTERVENTIONAL
primary_condition: Obesity
countries: Netherlands
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02783053.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02783053"
ct_last_update_post_date: 2016-10-10
last_seen_at: "2026-05-12T07:12:06.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Metformin and Core Temperature in Obese and Lean Males

**NCT ID:** [NCT02783053](https://clinicaltrials.gov/study/NCT02783053)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 18
- **Lead Sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Conditions:** Obesity
- **Start Date:** 2015-10
- **Completion Date:** 2016-06
- **CT.gov Last Update:** 2016-10-10

## Brief Summary

Metformin is known to increase 18F-FDG uptake in subjects using metformin in retrospective trials.

In this study the researchers aim to investigate the influence of metformin (500 mg 1/day) on temperature in the colon, glucose uptake in the colon and energy expenditure in healthy lean (BMI \< 24kg/m2) or obese subjects (BMI\>28kg/m2). The investigators will measure 18F-FDG uptake in the colon, temperature in the colon, insulin sensitivity and energy expenditure before after using metformin.

## Detailed Description

Obesity and diabetes mellitus type 2 (DM2) are health problems with a tremendous impact. Many attempts have been made to combat obesity and DM2, however, a breakthrough therapy is still lacking.

Obesity is the result of an imbalance between energy intake and energy expenditure. 18F-fluorodeoxy-d-glucose (18F-FDG) positron emission tomography computed tomography (PET-CT) pinpoint areas with high glucose turnover. Physiological 18F-FDG accumulation is frequently observed in the colon. Therefore, the colon might play an important role in increasing energy expenditure by consuming calories. However, the possibility of the colon as an energy dissipating tissue has not yet been explored. The colon could become an interesting new target of research to find a method to combat obesity.

Metformin is one of the few drugs in the treatment of DM2 that is associated with moderate weight loss. Interestingly, patients using metformin show an increased 18F-FDG-uptake in the colon. Whether this higher uptake of glucose also cause an increase in core temperature and/or an increase in energy expenditure is not known. The cause for this increase in glucose uptake in the colon by metformin use is unknown. Also, it is unknown whether this increase in glucose uptake results in an increased energy expenditure and/or an increase in core body temperature.

Objective: In this study the researchers aim to investigate the influence of metformin (500 mg 1/day) on temperature in the colon, glucose uptake in the colon and energy expenditure in healthy lean (BMI \< 24kg/m2) or obese subjects (BMI\>28kg/m2). The investigators will measure 18F-FDG uptake in the colon, temperature in the colon, insulin sensitivity and energy expenditure before after using metformin.

## Eligibility

- **Minimum age:** 50 Years
- **Sex:** MALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Male
* Caucasian origin
* Subjects should be able and willing to give informed consent
* \> 50 years old
* BMI\< 24 kg/m2 or \> 28 kg/m2

Exclusion Criteria:

* Renal failure (GFR\< 60ml/min)
* Liver insufficiency (AST or alanine aminotransferase 3 times upper value)
* Chronic use of drugs or medication
* Diabetes mellitus
* Lactate acidosis or precoma diabeticum in medical history
* Acute or chronic diseases such as: dehydration, severe infection, shock, heartfailure, pulmonary insufficiency, recent heart attack
* Alcoholism
```

## Arms

- **Metformin use** (OTHER) — The investigators compare the use of metformin vs no metformin
- **Lean or Obese** (NO_INTERVENTION) — The investigators compare the effect of metformin on 18F-FDG uptake between lean and obese men.

## Interventions

- **Metformin** (DRUG) — Metformin vs no metformin

## Primary Outcomes

- **18F-FDG uptake** _(time frame: 1 week)_ — Difference in 18F-FDG uptake as registered by 18F-FDG PET-CT before and after 7 days of daily metformin use.

## Secondary Outcomes

- **Core temperature using a temperature pill** _(time frame: 48 hours)_
- **Correlation core temperature and 18F-FDG uptake** _(time frame: 1 week)_
- **Energy expenditure (kcal/day) using ventilated hood** _(time frame: 30 minutes)_
- **Correlation between 18F-FDG uptake and energy expenditure** _(time frame: 1 week)_

## Locations (1)

- Academic Medical Center, Amsterdam, Netherlands

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.academic medical center|amsterdam||netherlands` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02783053.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02783053*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*